Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. director and CEO Steven Lo received new equity awards as part of his compensation. He was granted stock options for 1,543,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. These options vest 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030.
Lo also received a grant of 846,500 shares of common stock upon vesting of restricted stock units. Those units vest 25% on each anniversary of the vesting commencement date of March 16, 2026, fully vesting on the fourth anniversary. Following these awards, he directly holds 2,634,059 common shares and 1,543,000 options, plus an indirect holding of 100,000 shares through the Lo Family Trust.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported equity awards rather than open-market trades. He received a stock option covering 410,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030.
He also acquired 200,000 shares of common stock at no cash cost in connection with restricted stock units, which are scheduled to vest 25% on each anniversary of the March 16, 2026 vesting commencement date until the fourth anniversary. Following these awards, he directly holds 931,225 common shares, with additional indirect holdings of 51,465 shares in joint tenancy and 9,060 shares held by his spouse.
Vaxart, Inc.’s Chief Financial Officer, Jeroen Nicolaas Grasman, reported equity compensation grants. He was awarded 227,000 shares of Common Stock upon vesting of restricted stock units, bringing his direct Common Stock holdings to 577,000 shares.
He also received a stock option covering 455,000 shares of Common Stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The restricted stock units vest 25% on March 16, 2026 and then annually so they are fully vested on the fourth anniversary, while the option vests 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030. These are compensation-related awards rather than open-market purchases.
Vaxart, Inc. reported that Chief Medical Officer James F. Cummings received new equity awards on March 16, 2026. He was granted stock options for 455,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030. He also received 227,000 shares of common stock through vesting of restricted stock units, which vest 25% on each anniversary of March 16, 2026 over four years. Following these grants, he holds 964,792 shares of common stock directly.
Vaxart, Inc. SVP and General Counsel Edward B. Berg received new equity awards as part of his compensation. On March 16, 2026, he was granted 115,000 shares of common stock upon vesting of restricted stock units, with 25% of the units vesting on each anniversary of the March 16, 2026 vesting commencement date until fully vested after four years.
He was also granted a stock option for 225,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments so it is fully vested by March 16, 2030. Following these grants, Berg directly holds 799,858 common shares.
Vaxart, Inc. files its Annual Report describing progress on its oral tablet vaccine pipeline and regulatory environment. The company focuses on norovirus, COVID-19, influenza and HPV using its VAAST oral adenovirus-based platform to induce mucosal and systemic immunity via enteric‑coated tablets.
Vaxart reports positive Phase 1 data for a second‑generation bivalent norovirus vaccine showing large increases in functional antibodies and fecal IgA, and outlines plans to advance development with additional funding or partners. It also details a large BARDA‑funded Phase 2b COVID‑19 booster study using an oral KP.2‑targeted candidate versus an approved mRNA comparator, where about 5,400 adults were enrolled before U.S. authorities halted further enrollment but allowed 12‑month follow‑up to continue under a contract currently funded up to $316.0 million.
The filing further reviews prior BARDA‑funded influenza challenge data, an early HPV therapeutic vaccine program, in‑house and outsourced GMP manufacturing capabilities, extensive U.S. and foreign regulatory requirements, and a competitive landscape where no vaccines yet exist for norovirus or HPV therapy. As of June 30, 2025, non‑affiliate market value of common stock was $102,712,906 at $0.45 per share, and 240,634,372 shares were outstanding as of March 6, 2026.
Vaxart reported a strong turnaround for 2025, moving to profitability and highlighting progress in its oral vaccine pipeline. Revenue rose to $237.3 million from $28.7 million in 2024, driving net income of $16.3 million versus a prior-year net loss of $66.9 million. Earnings were $0.07 per basic and diluted share.
The company ended 2025 with cash, cash equivalents and investments of $63.8 million and stated it has runway into the second quarter of 2027. Vaxart highlighted a worldwide collaboration with Dynavax for its COVID-19 oral pill vaccine and expects topline data from a 400-person Phase 2b sentinel cohort in early Q2 2026, with full efficacy and safety readout from about 5,000 participants expected in the fourth quarter of 2026. The company also reported positive norovirus vaccine data in lactating women showing passive antibody transfer to infants.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported an automatic share withholding tied to restricted stock units (RSUs). On February 2, 2026, 7,965 shares of common stock were withheld at $0.6085 per share to satisfy income tax obligations upon RSU vesting. After this transaction, he beneficially owned 737,792 common shares, which includes 75,618 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan. The transaction was reported as directly held ownership.
Vaxart, Inc. SVP and General Counsel Edward B. Berg reported a routine tax-related share withholding. On February 2, 2026, 9,265 shares of common stock were withheld at $0.6085 per share to cover income tax obligations from vested RSUs. After this transaction, Berg directly beneficially owned 684,858 common shares, which includes 70,781 shares acquired through Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. senior vice president and chief scientific officer Sean Tucker reported a routine share withholding tied to restricted stock units (RSUs). On February 2, 2026, 9,265 shares of Vaxart common stock were withheld by the company at $0.6085 per share to cover income tax obligations upon RSU vesting.
After this tax-related withholding, Tucker beneficially owned 731,225 common shares directly. He also reported indirect holdings of 51,465 shares in joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares held by his spouse.